GlassScriptPhysician profile
Minhaj Siddiqi
NPI 1598858458
$3,054.18
in general payments reported to CMS, 2019-2025
14 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $1,054 · 2021: $61.12 · 2022: $75.57 · 2023: $225 · 2024: $183 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $589 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $589.13 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $580.87 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $415.97 | 2020-2025 | Caplyta |
| Allergan, INC. | $361.89 | 2019-2020 | |
| Abbvie INC. | $342.55 | 2021-2025 | Vraylar |
| Alkermes, INC. | $240.59 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $233.90 | 2019-2020 | |
| Lundbeck LLC | $231.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $216.88 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $181.13 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $95.86 | 2019-2020 | |
| Indivior INC. | $59.64 | 2019-2020 | |
| Shire North American Group INC | $46.33 | 2019 | |
| Vanda Pharmaceuticals INC. | $31.47 | 2020 | |
| Eisai INC. | $15.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minhaj Siddiqi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.